We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

User:Estelle Metzger/Sandbox

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 5: Line 5:
Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1<ref name="Bernd">doi: 10.1021/jm5018779</ref>.
Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1<ref name="Bernd">doi: 10.1021/jm5018779</ref>.
-
Pour ajouter une référence : <ref>Rentrer doi:... de la publi</ref> et si on veut utiliser la réf plusieurs fois, il faut lui donner un nom
 
== Humanized Roco4 ==
== Humanized Roco4 ==
Line 28: Line 27:
== LRRK2-IN-1 ==
== LRRK2-IN-1 ==
-
 
+
[[Image:4K4-270.png|thumb|LRRK2-IN-1 structure]]
-
<scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold. [[Image:4K4-270.png|thumb|LRRK2-IN-1 structure]]
+
<scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold.
The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier.
The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier.
The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure <ref name="Bernd"/>.
The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure <ref name="Bernd"/>.

Revision as of 15:14, 26 January 2017

Humanized Roco4 bound to LRRK2-IN-1

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A. Structural Characterization of LRRK2 Inhibitors. J Med Chem. 2015 May 1. PMID:25897865 doi:http://dx.doi.org/10.1021/jm5018779
  2. Gilsbach BK, Kortholt A. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci. 2014 May 5;7:32. doi: 10.3389/fnmol.2014.00032. eCollection, 2014. PMID:24847205 doi:http://dx.doi.org/10.3389/fnmol.2014.00032

Proteopedia Page Contributors and Editors (what is this?)

Estelle Metzger

Personal tools